iScience (Sep 2021)

Single-cell transcriptome identifies FCGR3B upregulated subtype of alveolar macrophages in patients with critical COVID-19

  • Nasna Nassir,
  • Richa Tambi,
  • Asma Bankapur,
  • Saba Al Heialy,
  • Noushad Karuvantevida,
  • Hamda Hassan Khansaheb,
  • Binte Zehra,
  • Ghausia Begum,
  • Reem Abdel Hameid,
  • Awab Ahmed,
  • Zulfa Deesi,
  • Abdulmajeed Alkhajeh,
  • K.M. Furkan Uddin,
  • Hosneara Akter,
  • Seyed Ali Safizadeh Shabestari,
  • Omar Almidani,
  • Amirul Islam,
  • Mellissa Gaudet,
  • Richard Kumaran Kandasamy,
  • Tom Loney,
  • Ahmad Abou Tayoun,
  • Norbert Nowotny,
  • Marc Woodbury-Smith,
  • Proton Rahman,
  • Wolfgang M. Kuebler,
  • Mahmood Yaseen Hachim,
  • Jean-Laurent Casanova,
  • Bakhrom K. Berdiev,
  • Alawi Alsheikh-Ali,
  • Mohammed Uddin

Journal volume & issue
Vol. 24, no. 9
p. 103030

Abstract

Read online

Summary: Understanding host cell heterogeneity is critical for unraveling disease mechanism. Utilizing large-scale single-cell transcriptomics, we analyzed multiple tissue specimens from patients with life-threatening COVID-19 pneumonia, compared with healthy controls. We identified a subtype of monocyte-derived alveolar macrophages (MoAMs) where genes associated with severe COVID-19 comorbidities are significantly upregulated in bronchoalveolar lavage fluid of critical cases. FCGR3B consistently demarcated MoAM subset in different samples from severe COVID-19 cohorts and in CCL3L1-upregulated cells from nasopharyngeal swabs. In silico findings were validated by upregulation of FCGR3B in nasopharyngeal swabs of severe ICU COVID-19 cases, particularly in older patients and those with comorbidities. Additional lines of evidence from transcriptomic data and in vivo of severe COVID-19 cases suggest that FCGR3B may identify a specific subtype of MoAM in patients with severe COVID-19 that may present a novel biomarker for screening and prognosis, as well as a potential therapeutic target.

Keywords